These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Emergent properties of proteostasis in managing cystic fibrosis. Balch WE; Roth DM; Hutt DM Cold Spring Harb Perspect Biol; 2011 Feb; 3(2):. PubMed ID: 21421917 [TBL] [Abstract][Full Text] [Related]
4. Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease. Strub MD; McCray PB Genes (Basel); 2020 May; 11(5):. PubMed ID: 32414011 [TBL] [Abstract][Full Text] [Related]
5. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine. Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567 [TBL] [Abstract][Full Text] [Related]
6. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Southern KW; Murphy J; Sinha IP; Nevitt SJ Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662 [TBL] [Abstract][Full Text] [Related]
7. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis. Cuyx S; De Boeck K Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727 [TBL] [Abstract][Full Text] [Related]
8. The proteome speciation of an immortalized cystic fibrosis cell line: New perspectives on the pathophysiology of the disease. Puglia M; Landi C; Gagliardi A; Breslin L; Armini A; Brunetti J; Pini A; Bianchi L; Bini L J Proteomics; 2018 Jan; 170():28-42. PubMed ID: 28970102 [TBL] [Abstract][Full Text] [Related]
9. Targets for cystic fibrosis therapy: proteomic analysis and correction of mutant cystic fibrosis transmembrane conductance regulator. Collawn JF; Fu L; Bebok Z Expert Rev Proteomics; 2010 Aug; 7(4):495-506. PubMed ID: 20653506 [TBL] [Abstract][Full Text] [Related]
10. Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis. Cai ZW; Liu J; Li HY; Sheppard DN Acta Pharmacol Sin; 2011 Jun; 32(6):693-701. PubMed ID: 21642944 [TBL] [Abstract][Full Text] [Related]
11. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets. Hanrahan JW; Sato Y; Carlile GW; Jansen G; Young JC; Thomas DY Expert Opin Ther Targets; 2019 Aug; 23(8):711-724. PubMed ID: 31169041 [No Abstract] [Full Text] [Related]
12. Correcting the F508del-CFTR variant by modulating eukaryotic translation initiation factor 3-mediated translation initiation. Hutt DM; Loguercio S; Roth DM; Su AI; Balch WE J Biol Chem; 2018 Aug; 293(35):13477-13495. PubMed ID: 30006345 [TBL] [Abstract][Full Text] [Related]
13. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence. Kotha K; Clancy JP Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658 [TBL] [Abstract][Full Text] [Related]
14. Silencing of the Hsp70-specific nucleotide-exchange factor BAG3 corrects the F508del-CFTR variant by restoring autophagy. Hutt DM; Mishra SK; Roth DM; Larsen MB; Angles F; Frizzell RA; Balch WE J Biol Chem; 2018 Aug; 293(35):13682-13695. PubMed ID: 29986884 [TBL] [Abstract][Full Text] [Related]
15. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
17. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
18. Unravelling druggable signalling networks that control F508del-CFTR proteostasis. Hegde RN; Parashuraman S; Iorio F; Ciciriello F; Capuani F; Carissimo A; Carrella D; Belcastro V; Subramanian A; Bounti L; Persico M; Carlile G; Galietta L; Thomas DY; Di Bernardo D; Luini A Elife; 2015 Dec; 4():. PubMed ID: 26701908 [TBL] [Abstract][Full Text] [Related]
19. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation. Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis. Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]